Valuation: Pfizer Inc

Market Cap 14TCr 13TCr 12TCr 11TCr 20TCr 13,74900Cr 21TCr 1,39500Cr 55TCr 6,81800Cr 54TCr 53TCr 23,55800Cr P/E 2026 *
12.8x
P/E 2027 * 13.3x
Enterprise Value 19TCr 17TCr 16TCr 15TCr 27TCr 18,46500Cr 28TCr 1,87400Cr 73TCr 9,15700Cr 73TCr 71TCr 31,63800Cr EV / Sales 2026 *
3.13x
EV / Sales 2027 * 3.15x
Free-Float
59.06%
Yield 2026 *
6.82%
Yield 2027 * 6.88%

Last Transcript: Pfizer Inc

Manager TitleAgeSince
Chief Executive Officer 64 01/01/2019
Director of Finance/CFO 60 02/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2007
Director TitleAgeSince
Director/Board Member 68 01/09/2007
Director/Board Member 62 27/09/2013
Chairman 64 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.93%+3.85%+51.05%+166.24% 1,08900Cr
+0.29%+6.43%+60.47%+52.87% 64TCr
+2.45%+2.77%+39.61%+74.48% 47TCr
+0.10%+11.19%+42.43%+36.59% 36TCr
+0.63%+4.71%+38.56%+44.11% 30TCr
+1.29%+2.87%+17.10%+16.81% 27TCr
-0.47%+4.19%-4.04%-39.04% 23TCr
+4.48%+7.33%+30.47%+66.31% 21TCr
+2.91%+3.10%+18.84%+74.76% 17TCr
Average +1.60%+5.07%+32.72%+54.79% 41.46TCr
Weighted average by Cap. +1.57%+5.14%+41.02%+79.95%

Financials

2026 *2027 *
Net sales 6.17TCr 5.42TCr 5.05TCr 4.64TCr 8.7TCr 5,89900Cr 8.85TCr 60TCr 23TCr 2,92500Cr 23TCr 23TCr 10,10700Cr 5.94TCr 5.21TCr 4.85TCr 4.46TCr 8.36TCr 5,67200Cr 8.51TCr 58TCr 23TCr 2,81300Cr 22TCr 22TCr 9,71800Cr
Net income 1.06TCr 933.15Cr 868.96Cr 799.24Cr 1.5TCr 1,01600Cr 1.52TCr 10TCr 4.04TCr 50TCr 3.99TCr 3.91TCr 1,74100Cr 1.03TCr 902.13Cr 840.07Cr 772.67Cr 1.45TCr 98TCr 1.47TCr 9.97TCr 3.9TCr 49TCr 3.86TCr 3.78TCr 1,68300Cr
Net Debt 4.94TCr 4.33TCr 4.03TCr 3.71TCr 6.96TCr 4,71600Cr 7.07TCr 48TCr 19TCr 2,33900Cr 19TCr 18TCr 8,08100Cr 4.32TCr 3.79TCr 3.53TCr 3.24TCr 6.08TCr 4,12400Cr 6.19TCr 42TCr 16TCr 2,04500Cr 16TCr 16TCr 7,06600Cr
Logo Pfizer Inc
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (42.9%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (28%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (26.9%); - other (2.2%). The United States accounts for 59.2% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-